Novel anti-coagulant clears hurdle
ATLANTA -- Duke University Medical Center cardiologists report that an experimental anti-coagulant that prevents the formation of blood clots earlier in the coagulation process than other agents has cleared another hurdle in becoming a potential new treatment for patients with coronary artery disease.... The new agent, code-named DX-9065a, inhibits the action of Factor Xa (as in Roman numeral X)...(Stockholm, Sweden, 3 September 2001) New data on the use of the novel oral anticoagulant Exanta, for stroke prevention in patients with non-valvular atrial fibrillation, were presented today at the 23rd European Society of Cardiology (ESC) meeting in Stockholm.¹ The three-month phase II, SPORTIF II, data show that Exanta is well tolerated in patients over an extended period of time, with co...New data support the efficacy and safety of the novel oral anticoagulant Exanta
(Mlndal, Sweden, 10 July 2001) The presentation of a wide range of data at the 18th International Society on Thrombosis and Haemostasis meeting (ISTH) in Paris this week, provided new evidence to support the efficacy and safety of Exanta, which is set to be the first new oral anticoagulant since warfarin was introduced over 50 years ago.... ...Exanta, an oral direct thrombin inhibitor, is curren...First large-scale clinical study establishes the efficacy of the new oral anticoagulant H 376/95
. European multi-centre trial demonstrates H 376/95 compares well with dalteparin in prevention of venous thromboembolism in orthopaedic surgery. . .The oral direct thrombin inhibitor H 376/95, the first new oral anticoagulant for 50 years, is effective in preventing venous thrombo-embolism in patients undergoing total hip or total knee replacement surgery, according to data presented for the fi...